JP2019524131A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524131A5
JP2019524131A5 JP2019507161A JP2019507161A JP2019524131A5 JP 2019524131 A5 JP2019524131 A5 JP 2019524131A5 JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019507161 A JP2019507161 A JP 2019507161A JP 2019524131 A5 JP2019524131 A5 JP 2019524131A5
Authority
JP
Japan
Prior art keywords
strain
poxvirus
nucleic acid
vaccinia virus
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019507161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524131A (ja
JP7023929B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/046163 external-priority patent/WO2018031694A1/en
Publication of JP2019524131A publication Critical patent/JP2019524131A/ja
Publication of JP2019524131A5 publication Critical patent/JP2019524131A5/ja
Priority to JP2022017693A priority Critical patent/JP7395628B2/ja
Application granted granted Critical
Publication of JP7023929B2 publication Critical patent/JP7023929B2/ja
Priority to JP2023200433A priority patent/JP7631485B2/ja
Priority to JP2025016649A priority patent/JP2025072482A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019507161A 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用 Active JP7023929B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022017693A JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662372408P 2016-08-09 2016-08-09
US62/372,408 2016-08-09
US201762519010P 2017-06-13 2017-06-13
US62/519,010 2017-06-13
PCT/US2017/046163 WO2018031694A1 (en) 2016-08-09 2017-08-09 Chimeric poxvirus compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022017693A Division JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2019524131A JP2019524131A (ja) 2019-09-05
JP2019524131A5 true JP2019524131A5 (enExample) 2020-09-17
JP7023929B2 JP7023929B2 (ja) 2022-02-22

Family

ID=61163330

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507161A Active JP7023929B2 (ja) 2016-08-09 2017-08-09 キメラポックスウイルス組成物及びその使用
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022017693A Active JP7395628B2 (ja) 2016-08-09 2022-02-08 キメラポックスウイルス組成物及びその使用
JP2023200433A Active JP7631485B2 (ja) 2016-08-09 2023-11-28 キメラポックスウイルス組成物及びその使用
JP2025016649A Pending JP2025072482A (ja) 2016-08-09 2025-02-04 キメラポックスウイルス組成物及びその使用

Country Status (10)

Country Link
US (2) US12084687B2 (enExample)
EP (1) EP3497209A4 (enExample)
JP (4) JP7023929B2 (enExample)
KR (3) KR20250067190A (enExample)
CN (3) CN118834840A (enExample)
AU (3) AU2017311380A1 (enExample)
CA (1) CA3033512A1 (enExample)
MX (1) MX2019001672A (enExample)
RU (2) RU2021128158A (enExample)
WO (1) WO2018031694A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2934532B1 (en) 2012-12-20 2019-10-23 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP4122492A1 (en) 2015-02-25 2023-01-25 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CN111163803B (zh) 2017-08-11 2025-05-09 希望之城公司 表达car t细胞靶物的溶瘤病毒及其用途
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための配列決定法
CA3093093A1 (en) * 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2019213173A1 (en) * 2018-04-30 2019-11-07 City Of Hope Neural stem cell compositions including chimeric poxviruses for cancer treatment
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
GB2614309A (en) 2021-12-24 2023-07-05 Stratosvir Ltd Improved vaccinia virus vectors
WO2023213763A1 (en) * 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
KR20250052416A (ko) 2022-08-18 2025-04-18 트랜스진 키메라 폭스바이러스
WO2024245722A2 (en) * 2023-05-26 2024-12-05 Probiogen Ag Rapid selection system for the generation of recombinant enveloped viruses
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
WO2025184411A1 (en) 2024-02-27 2025-09-04 Calidi Biotherapeutics (Nevada), Inc. Serum-resistant eev viruses and uses thereof
WO2026107113A1 (en) 2024-11-12 2026-05-21 Calidi Biotherapeutics (Nevada), Inc. MODIFIED CELLS FOR PROGRAMMING EXTRA ENVELOPED VIRUSES (EEVs) AND THEIR USE FOR PRODUCING THE EEVs, THE PROGRAMMED EEVs AND USES THEREOF
CN120718864B (zh) * 2025-08-28 2025-11-28 山东农业大学 一种高度不成熟鸭坦布苏病毒及其培养方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
JP2003528605A (ja) 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
ATE365220T1 (de) * 2002-11-25 2007-07-15 Bavarian Nordic As Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus
MXPA05013879A (es) * 2003-06-18 2006-06-27 Genelux Corp Virus de la vaccinia recombinantes modificados y otros microorganismos, y usos de los mismos.
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
EP2212423B1 (en) * 2007-11-19 2015-02-11 Transgene SA Poxviral oncolytic vectors
JP5652830B2 (ja) 2010-04-09 2015-01-14 国立大学法人 東京大学 マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
EP2697368B1 (en) 2011-04-15 2019-06-05 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
NZ701949A (en) * 2012-05-18 2016-07-29 Otago Innovation Ltd Combination treatments and compositions for wound healing
WO2015103438A2 (en) * 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR20250067190A (ko) * 2016-08-09 2025-05-14 시티 오브 호프 키메라 폭스바이러스 조성물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2022065034A5 (enExample)
JP2025072482A5 (enExample)
JP2024026191A5 (enExample)
RU2019106319A (ru) Композиции химерного поксвируса и их применение
JP2015533841A5 (enExample)
Afonso et al. The genome of swinepox virus
Kaynarcalidan et al. Vaccinia virus: from crude smallpox vaccines to elaborate viral vector vaccine design
JP2022163182A5 (enExample)
JP2012509340A5 (enExample)
CN104762321A (zh) 基于CRISPR/Cas9系统靶向敲除KHV基因的敲除载体构建方法及其crRNA原件
EA201692359A1 (ru) Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса
FI3352776T3 (fi) Htt-repressoreita ja niiden käyttötapoja
JP2011087580A5 (enExample)
BR112016020688A2 (pt) Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc)
JP2015533297A5 (enExample)
JP2019527055A5 (enExample)
JP2011155981A5 (enExample)
JP2017524348A5 (enExample)
Stik et al. The oncogenic microRNA OncomiR-21 overexpressed during Marek's disease lymphomagenesis is transactivated by the viral oncoprotein Meq
JP2013523718A5 (enExample)
JP2015533791A5 (enExample)
WO2013030176A3 (en) Live attenuated influenza virus
JP2019500907A5 (enExample)
MX2024002641A (es) Uso de micro ácido ribonucleico (arn) para la regulación por disminución de la expresión de transgenes citotóxicos mediante el virus vaccinia ankara modificado (mva).
JP2024535145A5 (enExample)